SEC Form 4 · accession 0001246360-15-001816
SYNAGEVA BIOPHARMA CORP · GEVA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony Quinn
Officer — EVP, CMO & Head of R&D
Period of report
Apr 15, 2015
Accepted (ET)
Apr 17, 2015 · 5:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000911326
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 15, 2015 | M | 10,000 | $40.74 | A | 25,637 | D | |
| Common Stock | Apr 15, 2015 | S | 10,000 | $105.00 | D | 15,637 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $40.74 | Apr 15, 2015 | M | 10,000 | D | — | Jun 27, 2022 | Common Stock | 10,000 | 35,000 | D |
Explanation of responses
- F1The stock option exercise and sale of shares of the Company's common stock (the "Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 6, 2015.
- F2The Stock Option granted the reporting person an option to purchase 45,000 shares of Common Stock (the "Shares"). 25% of the total number of shares subject to the option vested and became exercisable on June 27, 2013 and 1/36 of the remainder of the shares subject to the option vest and become exercisable monthly thereafter.